Sanofi-Aventis and Nichi-Iko lay out plans for new Japanese generics venture
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis chose Nichi-Iko as its partner for entering the generics sector in Japan as it was attracted by the company's strong business growth, market presence, entrepreneurial spirit and know-how.
You may also be interested in...
Nichi-Iko Losses Slow Down At Nine-Month Stage
“The outlook remains uncertain,” one analyst has noted as troubled Japanese manufacturer Nichi-Iko published its nine-month financial results, even as the company’s domestic losses slowed down and its US Sagent unit improved its sales by double-digits.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.